China NMPA's CDE has approved Alphamab Oncology’s IND for the multicentre Phase I/II JSKN033-102 trial of JSKN033.

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142, a long-acting growth hormone.

Zura Bio has initiated the Phase II TibuSURE trial to assess tibulizumab, in treating systemic sclerosis (SSc) in adult patients.

XBiotech has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities in its Phase II trial.

Sorriso Pharmaceuticals announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.

Precision has gained the approval of its CTA in Hong Kong to study PBGENE-HBV in the Phase I trial for curing chronic hepatitis B.

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for obesity.

AI continued to be shown as an invaluable tool with the potential to accelerate clinical trials and improve patient care.

Marengo's Phase II trial is assessing T cell activator invikafusp alfa in the treatment of advanced PD-1 resistant solid tumours.

Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma delta CAR T-cell therapy for treating ccRCC.